Open access
Open access
Powered by Google Translator Translator

RCT | Discontinuation vs. continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis.

23 Nov, 2022 | 13:36h | UTC

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials – The Lancet Respiratory Medicine (free registration required)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.